PhotoPharmics Gets FDA Breakthrough Status for Parkinson’s PhotoTherapy
May 1, 2020
PhotoPharmics, a pioneer in specialized phototherapy, announced on April 29, that it has received FDA Breakthrough device designation for the company’s non-invasive Specialized Phototherapy Device.
“Hats off to Utah’s PhotoPharmics,” said Kelvyn Cullimore, president and CEO of BioUtah. “Earning this Breakthrough designation is a significant value driver for a privately-owned device company.”
“Our device is the first specialized phototherapy device to achieve this status,” said Kent Savage, CEO of PhotoPharmics. “Our focus is to help people with Parkinson’s improve function… we think this recognition by FDA validates our work.”
The prescription phototherapy for Parkinson’s patients is intended to be used an adjunct treatment with standard dopaminergic therapy and is designed primarily for home use.
Recent News
- Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
- BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
- Lessons in Innovation: Clark Turner’s Impact on Medical Imaging
- Merit Medical Acquires Biolife Delaware
- Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
